

# Phillip D Stricker

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2842277/phillip-d-stricker-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

95  
papers

5,268  
citations

43  
h-index

71  
g-index

101  
ext. papers

6,395  
ext. citations

6.1  
avg. IF

5.17  
L-index

#	Paper	IF	Citations
95	How Does Age Affect Urinary Continence following Robot-Assisted Radical Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires.. <i>Journal of Urology</i> , <b>2022</b> , 101097JU00000000000002391	2.5	0
94	Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium.. <i>European Urology Open Science</i> , <b>2022</b> , <i>35</i> , 59-67	0.9	1
93	Selection of patients for nerve sparing surgery in robot-assisted radical prostatectomy.. <i>BJU International</i> , <b>2022</b> , <i>3</i> , 6-18	0.9	2
92	Salvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes.. <i>BMC Urology</i> , <b>2022</b> , <i>22</i> , 28	2.2	2
91	Outcomes of Salvage Radical Prostatectomy after initial IRE Treatment for Recurrent Prostate Cancer.. <i>BJU International</i> , <b>2022</b> ,	5.6	1
90	Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase. <i>EBioMedicine</i> , <b>2021</b> , <i>72</i> , 103625	8.8	5
89	Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis. <i>Genome Medicine</i> , <b>2021</b> , <i>13</i> , 81	14.4	6
88	Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE). <i>World Journal of Urology</i> , <b>2021</b> , <i>39</i> , 1107-1114	4	2
87	The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. <i>European Urology</i> , <b>2021</b> , <i>80</i> , 488-498	10.2	21
86	Assessment of Periprostatic and Subcutaneous Adipose Tissue Lipolysis and Adipocyte Size from Men with Localized Prostate Cancer. <i>Cancers</i> , <b>2020</b> , <i>12</i> ,	6.6	4
85	Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (Ga-PSMA) positron-emission/computed tomography after radical prostatectomy with pathological node-positive extended lymph node dissection. <i>BJU International</i> , <b>2020</b> , <i>125</i> , 876-883	5.6	4
84	Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. <i>BJU International</i> , <b>2020</b> , <i>125</i> , 515-524	5.6	29
83	The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis. <i>Cancers</i> , <b>2020</b> , <i>12</i> ,	6.6	5
82	The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies. <i>Journal of Urology</i> , <b>2020</b> , <i>203</i> , 910-917	2.5	25
81	3-Year Freedom from Progression After Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial. <i>Journal of Nuclear Medicine</i> , <b>2020</b> , <i>61</i> , 866-872	8.9	43
80	Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. <i>BJU International</i> , <b>2020</b> , <i>125</i> , 206-214	5.6	45
79	Irreversible electroporation (IRE): a narrative review of the development of IRE from the laboratory to a prostate cancer treatment. <i>BJU International</i> , <b>2020</b> , <i>125</i> , 369-378	5.6	10

78	Combination of Peri-Tumoral and Intra-Tumoral Radiomic Features on Bi-Parametric MRI Accurately Stratifies Prostate Cancer Risk: A Multi-Site Study. <i>Cancers</i> , <b>2020</b> , 12,	6.6	18
77	Oncological and Quality-of-life Outcomes Following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-monitored Prospective Cohort. <i>European Urology Oncology</i> , <b>2020</b> , 3, 283-290	6.7	24
76	Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer). <i>BMJ Open</i> , <b>2020</b> , 10, e033667	3	5
75	p53 nuclear accumulation as an early indicator of lethal prostate cancer. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 578-583	8.7	3
74	Gallium-68-prostate-specific membrane antigen ( Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer. <i>BJU International</i> , <b>2019</b> , 124, 62-68	5.6	40
73	Vroege oncologische uitkomsten van [68Ga]PSMA-PET/CT-gestuurde salvagetherapie bij mannen met biochemisch recidief na radicale prostatectomie. <i>Tijdschrift Voor Urologie</i> , <b>2019</b> , 9, 2-8	0.2	
72	Diagnostic accuracy of Ga-prostate-specific membrane antigen (PSMA) positron-emission tomography (PET) and multiparametric (mp)MRI to detect intermediate-grade intra-prostatic prostate cancer using whole-mount pathology: impact of the addition of Ga-PSMA PET to mpMRI. <i>BJU International</i> , <b>2019</b> , 124 Suppl 1, 42-49	5.6	38
71	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). <i>European Urology</i> , <b>2019</b> , 76, 790-813	10.2	76
70	Metagenomic analysis reveals a rich bacterial content in high-risk prostate tumors from African men. <i>Prostate</i> , <b>2019</b> , 79, 1731-1738	4.2	20
69	Ga-HBEDD PSMA-11 PET/CT staging prior to radical prostatectomy in prostate cancer patients: Diagnostic and predictive value for the biochemical response to surgery. <i>British Journal of Radiology</i> , <b>2019</b> , 92, 20180667	3.4	10
68	Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade. <i>Journal of Nuclear Medicine</i> , <b>2019</b> , 60, 950-954	8.9	75
67	An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. <i>International Journal of Cancer</i> , <b>2019</b> , 144, 1151-1159	7.5	11
66	Results of a Prospective Phase 2 Pilot Trial of Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer Including Imaging Predictors of Treatment Response and Patterns of Progression. <i>Clinical Genitourinary Cancer</i> , <b>2019</b> , 17, 15-22	3.3	93
65	Preliminary Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Focal Therapy with Irreversible Electroporation. <i>European Urology Focus</i> , <b>2019</b> , 5, 585-591	5.1	13
64	Radiomic features on MRI enable risk categorization of prostate cancer patients on active surveillance: Preliminary findings. <i>Journal of Magnetic Resonance Imaging</i> , <b>2018</b> , 48, 818	5.6	56
63	Pair-matched patient-reported quality of life and early oncological control following focal irreversible electroporation versus robot-assisted radical prostatectomy. <i>World Journal of Urology</i> , <b>2018</b> , 36, 1383-1389	4	15
62	Enduring epigenetic landmarks define the cancer microenvironment. <i>Genome Research</i> , <b>2018</b> , 28, 625-637	9.7	60
61	Superior Biochemical Recurrence and Long-term Quality-of-life Outcomes Are Achievable with Robotic Radical Prostatectomy After a Long Learning Curve-Updated Analysis of a Prospective Single-surgeon Cohort of 2206 Consecutive Cases. <i>European Urology</i> , <b>2018</b> , 73, 664-671	10.2	38

60	Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. <i>Prostate</i> , <b>2018</b> , 78, 308-317	4.2	28
59	The Impact of Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. <i>Journal of Nuclear Medicine</i> , <b>2018</b> , 59, 82-88	8.9	210
58	Imaging: MRI improves cost and accuracy of prostate cancer biopsy. <i>Nature Reviews Urology</i> , <b>2018</b> , 15, 6-8	5.5	2
57	Altered mitochondrial genome content signals worse pathology and prognosis in prostate cancer. <i>Prostate</i> , <b>2018</b> , 78, 25-31	4.2	15
56	Focal irreversible electroporation as primary treatment for localized prostate cancer. <i>BJU International</i> , <b>2018</b> , 121, 716-724	5.6	49
55	Prostate cancer in 432 men aged . <i>BJU International</i> , <b>2018</b> , 122 Suppl 5, 35-41	5.6	8
54	Reduced sensitivity of multiparametric MRI for clinically significant prostate cancer in men under the age of 50. <i>Research and Reports in Urology</i> , <b>2018</b> , 10, 145-150	1.3	2
53	Whole-Genome Sequencing Reveals Elevated Tumor Mutational Burden and Initiating Driver Mutations in African Men with Treatment-Naïve, High-Risk Prostate Cancer. <i>Cancer Research</i> , <b>2018</b> , 78, 6736-6746	10.1	36
52	Impact on genitourinary function and quality of life following focal irreversible electroporation of different prostate segments. <i>Diagnostic and Interventional Radiology</i> , <b>2018</b> , 24, 268-275	3.2	11
51	Identifying the morphologic basis for radiomic features in distinguishing different Gleason grades of prostate cancer on MRI: Preliminary findings. <i>PLoS ONE</i> , <b>2018</b> , 13, e0200730	3.7	30
50	Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer. <i>BJU International</i> , <b>2017</b> , 119, 209-215	5.6	195
49	Diagnostic accuracy of multi-parametric MRI and transrectal ultrasound-guided biopsy in prostate cancer. <i>Lancet, The</i> , <b>2017</b> , 389, 767-768	4.0	3
48	A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy. <i>BJU International</i> , <b>2017</b> , 120, 774-781	5.6	68
47	Initial multicentre experience of gallium-PSMA PET/CT guided robot-assisted salvage lymphadenectomy: acceptable safety profile but oncological benefit appears limited. <i>BJU International</i> , <b>2017</b> , 120, 673-681	5.6	52
46	Predictive value of the 2014 International Society of Urological Pathology grading system for prostate cancer in patients undergoing radical prostatectomy with long-term follow-up. <i>BJU International</i> , <b>2017</b> , 120, 651-658	5.6	25
45	Radiomic features for prostate cancer detection on MRI differ between the transition and peripheral zones: Preliminary findings from a multi-institutional study. <i>Journal of Magnetic Resonance Imaging</i> , <b>2017</b> , 46, 184-193	5.6	82
44	Feasibility and safety of focal irreversible electroporation as salvage treatment for localized radio-recurrent prostate cancer. <i>BJU International</i> , <b>2017</b> , 120 Suppl 3, 51-58	5.6	18
43	Treatment Outcomes from Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 1972-1976	8.9	99

42	Loss of AZGP1 as a Superior Predictor of Relapse in Margin-Positive Localized Prostate Cancer. <i>Prostate</i> , <b>2016</b> , 76, 1491-1500	4.2	8
41	Assessment of the Performance of Magnetic Resonance Imaging/Ultrasound Fusion Guided Prostate Biopsy against a Combined Targeted Plus Systematic Biopsy Approach Using 24-Core Transperineal Template Saturation Mapping Prostate Biopsy. <i>Prostate Cancer</i> , <b>2016</b> , 2016, 3794738	1.9	12
40	Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer. <i>Aging</i> , <b>2016</b> , 8, 2702-2712	5.6	18
39	(68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. <i>BJU International</i> , <b>2016</b> , 117, 732-9	5.6	186
38	Combination of multiparametric MRI and transperineal template-guided mapping biopsy of the prostate to identify candidates for hemi-ablative focal therapy. <i>BJU International</i> , <b>2016</b> , 117, 48-54	5.6	25
37	Medium-term oncological outcomes for extended vs saturation biopsy and transrectal vs transperineal biopsy in active surveillance for prostate cancer. <i>BJU International</i> , <b>2015</b> , 115, 884-91	5.6	32
36	Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. <i>Journal of Nuclear Medicine</i> , <b>2015</b> , 56, 1185-90	8.9	409
35	Reply to Patrick H. Tuliao and Koon Ho Rha's letter to the editor re: James E. Thompson, Sam Egger, Maret B̄m, et al. Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single-surgeon study of	10.2	1
34	Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single-surgeon study of 1552 consecutive cases. <i>European Urology</i> , <b>2014</b> , 65, 521-31	10.2	113
33	A multinational, multi-institutional study comparing positive surgical margin rates among 22393 open, laparoscopic, and robot-assisted radical prostatectomy patients. <i>European Urology</i> , <b>2014</b> , 66, 450-6	10.2	85
32	Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. <i>Journal of Urology</i> , <b>2014</b> , 192, 67-74	2.5	166
31	The role of magnetic resonance imaging in the diagnosis and management of prostate cancer. <i>BJU International</i> , <b>2013</b> , 112 Suppl 2, 6-20	5.6	98
30	Outcomes of transperineal template-guided prostate biopsy in 409 patients. <i>BJU International</i> , <b>2013</b> , 112, 585-93	5.6	47
29	The impact of nerve sparing on incidence and location of positive surgical margins in radical prostatectomy. <i>BJU International</i> , <b>2012</b> , 109, 533-8	5.6	13
28	High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. <i>BJU International</i> , <b>2012</b> , 109, 1794-800	5.6	54
27	Location and pathological characteristics of cancers in radical prostatectomy specimens identified by transperineal biopsy compared to transrectal biopsy. <i>Journal of Urology</i> , <b>2012</b> , 188, 781-5	2.5	65
26	Low AZGP1 expression predicts for recurrence in margin-positive, localized prostate cancer. <i>Prostate</i> , <b>2011</b> , 71, 1638-45	4.2	29
25	Should experienced open prostatic surgeons convert to robotic surgery? The real learning curve for one surgeon over 3 years. <i>BJU International</i> , <b>2010</b> , 106, 378-84	5.6	68

24	Gene based prediction of clinically localized prostate cancer progression after radical prostatectomy. <i>Journal of Urology</i> , <b>2010</b> , 184, 1521-8	2.5	12
23	Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2010</b> , 19, 2611-22 <sup>4</sup>		119
22	HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer. <i>Molecular and Cellular Endocrinology</i> , <b>2009</b> , 301, 89-96	4.4	37
21	Immunohistochemical level of unsulfated chondroitin disaccharides in the cancer stroma is an independent predictor of prostate cancer relapse. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2008</b> , 17, 2488-97	4	23
20	Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. <i>Prostate</i> , <b>2008</b> , 68, 1421-9	4.2	54
19	Aberrant neuropeptide Y and macrophage inhibitory cytokine-1 expression are early events in prostate cancer development and are associated with poor prognosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2006</b> , 15, 711-6	4	53
18	Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. <i>Journal of the National Cancer Institute</i> , <b>2006</b> , 98, 1420-4	9.7	76
17	Cross-sectional analysis of sexual function after prostate brachytherapy. <i>Urology</i> , <b>2005</b> , 66, 377-81	1.6	22
16	Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. <i>Urology</i> , <b>2005</b> , 66, 1245-50	1.6	222
15	Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer. <i>International Journal of Cancer</i> , <b>2005</b> , 113, 415-22	7.5	55
14	The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome. <i>Cancer Research</i> , <b>2005</b> , 65, 2330-6	10.1	114
13	Membranous expression of secreted Frizzled-related protein 4 predicts for good prognosis in localized prostate cancer and inhibits PC3 cellular proliferation in vitro. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 615-25	12.9	71
12	Loss of BMP2, Smad8, and Smad4 expression in prostate cancer progression. <i>Prostate</i> , <b>2004</b> , 59, 234-42	4.2	91
11	Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. <i>Molecular Cancer Therapeutics</i> , <b>2004</b> , 3, 921-32	6.1	52
10	Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma. <i>Cancer</i> , <b>2003</b> , 98, 2560-5	6.4	75
9	Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. <i>Oncogene</i> , <b>2003</b> , 22, 6005-12	9.2	86
8	A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. <i>Journal of Urology</i> , <b>2003</b> , 170, 1798-803	2.5	308
7	Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. <i>Cancer Research</i> , <b>2003</b> , 63, 4196-203	10.1	166

6	International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 3206-12	2.2	182
5	Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 3692-705	2.2	68
4	Prostate cancer diagnosis and management. <i>Lancet, The</i> , <b>1997</b> , 349, 1681-7	4.0	68
3	Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer. <i>Urology</i> , <b>1996</b> , 48, 957-61; discussion 961-2	1.6	61
2	Antiproliferative effects of bacillus Calmette-Guérin and interferon alpha 2b on human bladder cancer cells in vitro. <i>Cancer Immunology, Immunotherapy</i> , <b>1995</b> , 41, 309-16	7.4	36
1	Injectable collagen for type 3 female stress incontinence: the first 50 Australian patients. <i>Medical Journal of Australia</i> , <b>1993</b> , 158, 89-91	4	52